Marshall Wace North America’s GSK GSK Stock Holding History

Marshall Wace North America’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-278,043	Closed	-$13.1M	–	1408
2020 Q3	$13.1M	Buy	+278,043	New	+$13.9M	0.08%	241
2019 Q4	–	Sell	-34,362	Closed	-$1.83M	–	1402
2019 Q3	$1.83M	Buy	+34,362	New	+$1.77M	0.01%	563
2019 Q2	–	Sell	-1,200	Closed	-$62K	–	1318
2019 Q1	$62K	Buy	+1,200	New	+$60K	﹤0.01%	1218
2018 Q3	–	Sell	-42,862	Closed	-$2.16M	–	1087
2018 Q2	$2.16M	Sell	42,862 -373,700	-90%	-$18.8M	0.01%	745
2018 Q1	$20.3M	Sell	416,562 -1,526,826	-79%	-$71.1M	0.1%	234
2017 Q4	$86.2M	Buy	1,943,388 +381,165	+24%	+$17.6M	0.48%	42
2017 Q3	$80.1M	Buy	1,562,223 +666,630	+74%	+$33.8M	0.51%	24
2017 Q2	$48.1M	Buy	895,593 +534,471	+148%	+$28.5M	0.35%	69
2017 Q1	$19M	Buy	+361,122	New	+$18.3M	0.15%	181

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Marshall Wace North America's GSK Position: Q4 2020 in Review

Marshall Wace North America sold out of GSK (GSK) in Q4 2020, closing a stake of 278,043 shares — an estimated $13.1M sold.

Marshall Wace North America first reported a position in GSK in Q1 2017 and held it in 9 quarters. The position peaked at $86.2M in Q4 2017. 819 funds tracked by Wall St. Rank hold GSK as of Q4 2020.

Marshall Wace North America reported no remaining GSK position as of Q4 2020 after selling out during the quarter.
Marshall Wace North America sold 278,043 GSK shares in Q4 2020, an estimated $13.1M.
Marshall Wace North America first reported a position in GSK in Q1 2017 and held it in 9 quarters.
Marshall Wace North America's GSK position peaked at $86.2M in Q4 2017.
819 funds tracked by Wall St. Rank held GSK as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.